Hussman Strategic Advisors Inc. Invests $939,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Hussman Strategic Advisors Inc. purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, HoldingsChannel reports. The firm purchased 10,500 shares of the medical equipment provider’s stock, valued at approximately $939,000.

A number of other hedge funds also recently modified their holdings of the business. Janus Henderson Group PLC lifted its holdings in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after purchasing an additional 257,022 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after purchasing an additional 32,551 shares during the period. Reinhart Partners LLC. lifted its holdings in shares of Lantheus by 9.9% during the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock worth $122,280,000 after purchasing an additional 123,282 shares during the period. Swedbank AB lifted its holdings in shares of Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after purchasing an additional 385,000 shares during the period. Finally, Portolan Capital Management LLC lifted its holdings in shares of Lantheus by 6.1% during the third quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider’s stock worth $73,629,000 after purchasing an additional 38,776 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Trading Down 0.6 %

LNTH opened at $80.88 on Friday. Lantheus Holdings, Inc. has a 1-year low of $56.06 and a 1-year high of $126.89. The company has a market cap of $5.62 billion, a P/E ratio of 13.46 and a beta of 0.44. The company has a fifty day moving average price of $90.60 and a two-hundred day moving average price of $97.20.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on LNTH shares. JMP Securities restated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial restated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. Finally, StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.